Robot-Assisted Surgery: A Promising Tool Yet to Prove Superiority

By HEOR Staff Writer

September 7, 2023

Robot-Assisted Surgery (RAS) is a technologically advanced form of minimally invasive surgery, offering a higher degree of precision compared to traditional laparoscopic methods. RAS allows surgeons to control the instruments of the robotic system remotely, providing a further minimally invasive surgical option for patients.

According to the World Health Organization (WHO), there are currently 19 known manufacturers of robotic systems designed to aid in surgical procedures. The most widely used among these is the da Vinci® Surgical System.

The Austrian Institute for Health Technology Assessment (AIHTA) report focused on the use of RAS in thoracic and visceral surgery. Thoracic surgery primarily treats conditions of the lungs, chest wall, and diaphragm, while visceral surgery focuses on diseases of abdominal organs, the gastrointestinal tract, endocrine organs, the abdominal wall, and the peritoneum.
However, the report revealed mixed results regarding the effectiveness and safety of RAS. While RAS claims to reduce readmissions and shorten hospital stays, no statistically significant differences were detected compared to laparoscopic or open procedures.

On the positive side, RAS resulted in decreased blood loss in certain procedures and fewer postoperative complications in others. However, it also tends to have a higher mean cost per procedure than conventional surgical methods.

The report concluded that while RAS might present potential advantages for certain indications and outcomes, most of the claimed benefits could not be materialised. Moreover, the financial and environmental implications must be considered in purchasing decisions.

In conclusion, while RAS is a promising tool in the field of surgery, more comprehensive studies with larger sample sizes and longer follow-up times are needed to conclusively determine its superiority over traditional surgical methods.

Reference url

Recent Posts

mifepristone safety study
Mifepristone Safety Study: Ensuring Continued Regulatory Oversight

By João L. Carapinha

June 6, 2026

The mifepristone safety study launched by the FDA in April 2026 is actively collecting high-quality real-world data to determine whether the current Risk Evaluation and Mitigation Strategy (REMS) program still strikes the right balance between clinical benefits and potential harms. S...
HIV prevention access strategies
HIV Prevention Access Strategies Through Collaborative Partnerships in South Africa

By João L. Carapinha

June 6, 2026

HIV prevention access strategies have reached a pivotal moment in South Africa with the imminent launch of lenacapavir, a long-acting injectable administered twice yearly. This coordinated effort directly confronts the country’s immense HIV burden, including 7.8 million people living with the vir...
cancer productivity Asia-Pacific
Cancer Productivity Disparities in the Asia-Pacific Region

By João L. Carapinha

June 5, 2026

New research exposes a deepening divide in cancer productivity Asia-Pacific, where middle-income countries face rapidly escalating productivity losses from premature cancer deaths and disability, while high-income economies have begun to stabilise their burdens. Between 2010 and 2022, indirect ec...